Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients.
John R. Wingard(University of Florida Health), Kieren A. Marr(Freedom to Live), Javier Bolaños‐Meade(Johns Hopkins University), Joanne Kurtzberg, Edward A. Stadtmauer(University of Pennsylvania), Helen Leather(University of Florida), Janice Brown(Karolinska University Hospital), Adam Mendizabal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), John F. DiPersio(Washington University in St. Louis), Michael Boeckh(University of Washington), Thomas J. Walsh(Cornell University), Iris D. Gersten(Emmes (United States)), Richard T. Maziarz(Oregon Health & Science University), Lindsey R. Baden(Brigham and Women's Hospital), Dennis L. Confer(National Marrow Donor Program), Trudy N. Small(Memorial Sloan Kettering Cancer Center), Shelly L. Carter(Emmes (United States))
Cited by 91
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.2k
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
|Clinical Infectious Diseases|2005|3k